IC-MPGN clinical trials at UCSF

1 research study open to eligible people

IC-MPGN is a kidney disease where immune complexes cause inflammation in tiny blood vessels. UCSF is testing a drug called Iptacopan to see if it is safe and works well for people with this condition. This trial involves giving some participants the drug while others get a placebo.

Showing trials for

  • Iptacopan in Participants With IC-MPGN

    open to eligible people ages 12-60

    This study is designed as a multicenter, randomized, double-blind, parallel group, placebo-controlled study to evaluate the efficacy and safety of iptacopan (LNP023) in idiopathic immune complex mediated membranoproliferative glomerulonephritis.

    San Francisco 5391959, California 5332921 and other locations

Our lead scientists for IC-MPGN research studies include .

Last updated: